Compare 10X Genomics Inc (TXG) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Union Pacific Corporation — how do they compare? 10X Genomics Inc trades at $81.58 (market cap $10.07B), while Union Pacific Corporation trades at $277.92 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 16.4× 10X Genomics Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Union Pacific Corporation for 105 Days on average.
| TXG | UNP | |
|---|---|---|
Market Cap | $10.07B | $165.27B |
Volume | 5,657,286 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $97.74 | $310.62 |
52-Week Low | $11.48 | $216.37 |
Typical Hold Time | 92 Days | 105 Days |
Enterprise Value | $9.59B | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Union Pacific (UNP) trades at $274.68, down 0.7% with a bearish technical signal despite strong Q2 2026 earnings beat. The railroad operator maintains robust fundamentals with 28.85% net margin and 39.7% ROE, supported by $9.3B operating cash flow. Recent developments include battery-electric locomotive deployment and progress on the Norfolk Southern combination, while analyst consensus remains bullish with $332.10 price target.
UNP presents a compelling value opportunity with 21% upside to consensus target, though merger uncertainty and fuel cost pressures create near-term volatility. The company's irreplaceable infrastructure and dividend growth streak provide long-term stability, but investors should monitor regulatory approval of the Norfolk Southern deal and operating ratio pressures from rising diesel prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
